Oxidative stress in the cardiorenal metabolic syndrome

Current Hypertension Reports

Volumn 14, Issue 4, 2012, Pages 360-365

  Whaley Connell, Adam ^a   Sowers, James R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Aldosterone; Cardiorenal syndrome; Hypertension; Insulin resistance; Obesity; Oxidative stress; Redox control; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD VESSEL FUNCTION; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

BLOOD PRESSURE; CARDIO-RENAL SYNDROME; HUMANS; HYPERTENSION; INSULIN RESISTANCE; NADPH OXIDASE; OBESITY; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84865657612     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0279-2     Document Type: Article

References (49)

1. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA. 2002;288(21):2709-16. (Pubitemid 35403784)
2. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245-50. (Pubitemid 39202340)
3. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22:39-47.
4. McFarlane SI, Banerji M, Sowers Jr. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86(2):713-8. (Pubitemid 32207485)
5. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-96.
6. Sowers JR, Whaley-Connell A, Epstein M. The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776-83. Targeted paper highlighting aldosterone as critical in resistant hypertension.
7. Pulakat L, Demarco VG, Whaley-Connell A, Sowers Jr. The impact of over-nutrition on insulin metabolic signaling in the heart and the kidney. Cardiorenal Med. 2011;1(2):102-12. Seminal paper in a journal dedicated to cardiorenal metabolic syndrome.
8. Bomback AS, Klemmer PJ. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-Associated kidney disease. Am J Nephrol. 2009;30(2):140-6.
9. Whaley-Connell A, Sowers Jr. Aldosterone and risk for insulin resistance. Hypertension. 2011;58(6):998-1000.
10. Reaven GM, Chen YD. Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit? Circulation. 1996;93(10):1780-3. Important early paper highlighting a unique role for insulin resistance independent of diabetes and its contribution to heart disease. (Pubitemid 26154026)
11. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: How well do the emperor's clothes fit? Diabetes Care. 2004;27(4):1011-2. (Pubitemid 38420232)
12. Pulakat L, Demarco VG, Ardhanari S, Chockalingam A, Gul R, Whaley-Connell AT, Sowers Jr. Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol. 2011 Aug 3. Epub ahead of print.
13. Sowers Jr. The heart and the kidneys: Partners in disease? Cardiorenal Med. 2011;1(1):1-2.
14. Lambeth JD. Nox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropy. Free Radic Biol Med. 2007;43:332-47. (Pubitemid 46992767)
15. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: Specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:277-97. Very important paper reviewing the role of NADPH oxidase in health and disease.
16. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2) and systolic blood pressure in mice. Circ Res. 2001;89:408-14. Seminal paper defining the role for NADPH oxidase. (Pubitemid 34132656)
17. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev. 2007;87:245-313. (Pubitemid 46209993)
18. Hall JE, Brands MW, Dixon WN, Smith Jr. MJ. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension. 1993;22:292-9. (Pubitemid 23254076)
19. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;55:845-55.
20. Rocchini AP, Moorehead C, DeRemer S, Goodfriend TL, Ball DL. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension. 1990;15:861-6. (Pubitemid 20189470)
21. Rocchini AP, Marker P, Cervenka T. Time course of insulin resistance associated with feeding dogs a high-fat diet. Am J Physiol. 1997;272:E147-54.
22. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36-41.
23. Mollnau H,Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58-65.
24. Zhang HH, Huang J, Düvel K, Boback B, Wu S, Squillace RM, Wu CL, Manning BD. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One. 2009;4(7):e6189. Important paper highlighting the mTOR pathway.
25. Reisin E, Messerli FG, Ventura HO, Frohlich ED. Renal haemodynamic studies in obesity hypertension. J Hypertens. 1987;5:397-400. (Pubitemid 17126231)
26. Granger JP, West D, Scott J. Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. Hypertension. 1994;23:I8-11.
27. Schorr U, Blaschke K, Turan S, Distler A, Sharma AM. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens. 1998;16:1475-80. (Pubitemid 28470495)
28. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res. 1998;24:789-96. (Pubitemid 29016481)
29. Giacchetti GFE, Sardu C, Mariniello B, Garrapa GGM, Gatti C, Camilloni MA, Mantero F. Different gene expression of the RAS in human subcutaneous and visceral adipose tissue. Int J Obes Relat Metab Disord. 1999;23 suppl 5:S71.
30. Massiera F, Seydoux J, Geloen A, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology. 2001;142:5220-5. (Pubitemid 33131951)
31. Cooper R, McFarlane-Anderson N, Bennett FI, et al. ACE, angiotensinogen and obesity: A potential pathway leading to hypertension. J Hum Hypertens. 1997;11:107-11. (Pubitemid 27202252)
32. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, et al. Renin-Aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293(4):H2009-23. (Pubitemid 47605846)
33. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312-8. (Pubitemid 43740260)
34. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88(6):2364-72. (Pubitemid 36724399)
35. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51:161-7. (Pubitemid 351159920)
36. Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension. 2009;53(2):158-65.
37. Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, Kobayashi N, Shichiri M, Hirata Y. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: The possible role of local renin-Angiotensin system. Endocrinology. 2007;148:1688-96. (Pubitemid 46457130)
38. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-Angiotensin-II-Aldosterone system stimulation of reduced NADPH oxidase and cardiac remodeling. Endocrinology. 2007;148:3773-80. (Pubitemid 47105865)
39. Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, Ferrario CM, Sowers Jr. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol. 2009;296(5):F1013-22.
40. Nistala R, Whaley-Connell A. Sowers JR Redox control of renal function and hypertension. Antioxid Redox Signal. 2008;10 (12):2047-89.
41. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: Clinical implications and therapeutic possibilities. Diabetes Care. 2008;31 Suppl 2:S170-80.
42. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501. (Pubitemid 30165039)
43. Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ, Shah AM. Essential role of the NADPH oxidase subunit p47 (phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-Alpha. Circ Res. 2002;90:143-50. (Pubitemid 34627082)
44. Cohn JN. Reducing cardiovascular risk by blockade of the reninangiotensin-Aldosterone system. Adv Ther. 2007;24(6):1290-304. (Pubitemid 351618138)
45. Lastra G, Habibi J, Whaley-Connell A, Manrique C, Appesh L, Hayden MR, Rehmer J, Patel K, Ferrario CM, Sowers Jr. Direct renin inhibition reduces oxidative stress, and improves insulinstimulated glucose transport and insulin resistance in skeletal muscle in the TG(mRen2)27 rat. Endocrinology. 2009;150(6):2561-8.
46. Habibi J, Whaley-Connell A, Hayden MR, DeMarco VG, Schneider R, Sowers SD, Karuparthi P, Ferrario CM, Sowers Jr. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology. 2008;149(11):5643-53.
47. Abdellatif AA. The role of renin inhibition in treating the hypertensive patient with diabetes: A summary of preclinical and clinical evidence. Expert Rev Cardiovasc Ther. 2012;10(2):251-63.
48. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-62.
49. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362 (16):1477-90.